not used title
not used title
What you should know
Groups motivated by special interests (see NASHP) and backed by insurance companies (see AARP) are pushing states to adopt flawed price-setting schemes, often in the form of prescription drug affordability boards (PDABs). Establishing these boards wedges government-appointed bureaucrats between doctors and their patients while shortsightedly focusing on only one component of health care — all too curiously avoiding any review of or actions on abusive health insurance practices. This is not good news for patients.
The truth is that PDABs:
- Risk patients’ access to medicines. Prescription drug boards are government price setting schemes that let politicians set medicine prices with little accountability to, or input from, patients and their doctors. Under this scheme, an unelected board of bureaucrats evaluates the price of medicines and determines whether certain medicines and treatments are worth paying for, with the state coming between patients and the treatments their doctors prescribe.
- Reduce predictability for patients. Too many unanswered questions remain. What happens if a drug becomes unobtainable at the board’s arbitrarily set price, or board decisions result in reduced treatment options for patients? Or, what happens if middlemen reduce health insurance coverage for the non-price-controlled drugs that patients still need?
And that’s not all. Politically appointed boards like these take control away from patients and their doctors, leaving the access and affordability of life-saving medicines in the hands of each election cycle.
- Ignore the true reasons for high patient out-of-pocket costs. These boards fail to address the root problems facing patients — abusive practices of pharmacy benefit managers (PBMs). Too often, health insurers and PBMs:
- use harmful tactics, like accumulator adjustment and co-pay maximizer programs, to deny patients benefits of patient assistance programs.
- use utilization management tools, like requiring prior authorization or failing first on other therapies, which can create significant barriers between patients and the medicines their doctors prescribe.
- choose to pocket the tens of billions in rebates and discounts they receive on medicines for their own profit instead of sharing the savings with patients.
- Jeopardize development of new medicines. We are already seeing the impacts of price-setting policies at the federal level (Inflation Reduction Act), and state boards could have similar effects:
- Government price setting policies reduce biopharmaceutical companies’ ability to invest in the post-approval research required to see if they can be used in new ways, especially in disease areas like cancer.
- Analysis shows investments in research and development are already shifting away from small molecule medicines (pills and tablets) because of the IRA’s “pill penalty,” despite the benefit these types of medicines have for patients.
- One manufacturer has made clear they are “not going to do certain [clinical] trials … because it is becoming financially not viable [due to the IRA].”
Patients deserve better. Instead of adopting flawed price-setting schemes, states should implement common-sense reforms to make insurance work like insurance to safeguard patient access and affordability for the medicines their doctors prescribe.
Learn more.
Reid Porter
Reid Porter is senior director of public affairs at PhRMA, where he focuses on key policy priorities, member engagement and state media relations. He brings over two decades of experience leading communications and managing complex issues across the biopharmaceutical, technology and energy sectors. Porter holds a B.A. from Middlebury College, where he double‑majored in English and Spanish, and a graduate certificate in Publishing from Columbia University. Outside of work, he enjoys writing, traveling, cheering for the Green Bay Packers, playing and watching soccer, playing the violin, rereading Hemingway novels and spending time with family.
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
September 18, 2026
What AARP isn’t telling seniors about MFN
August 24, 2026
Policymakers should improve patient access and reject price controls
August 18, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
Insurers blame GLP-1s for rising costs. The data tells a different story.
August 14, 2026
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
August 7, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Voters continue to voice their concerns on government price controls
July 24, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
Message to USAging: Providers are raising concerns about coverage barriers
July 22, 2026
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
July 10, 2026
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
June 25, 2026
Guest Blog: Price controls won’t lower costs when insurers control access
June 25, 2026
Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.
June 24, 2026
MFN could disrupt the affordable medicines patients depend on
June 18, 2026
New “America Cures” ad: U.S. patients get new medicines first
June 15, 2026
Patients speak out: MFN won't address my affordability concerns
June 4, 2026
MFN price controls threaten American jobs and the U.S. economy
May 28, 2026
340B is growing, but it is unclear if Illinois patients benefit
May 27, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
State price-setting boards create more questions than answers
May 20, 2026
New analysis highlights access to new medicines in the United States and abroad
May 13, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"
April 24, 2026
MFN price controls would drain pensions and put retirements at risk
April 23, 2026
Survey confirms too many insured Americans face barriers to reliable health care
April 22, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
CMS undermines medical progress with MFN price controls
April 16, 2026
Trump Administration’s efforts to have other countries pay their fair share are underway
April 15, 2026
70% DENIED: How insurance denials are delaying and preventing care for millions of Americans
April 14, 2026
CMS’ MFN proposals won’t help seniors despite lofty promises
April 9, 2026
Voters voice concerns on government price controls
April 7, 2026
Virginia should be cautious about importing federal price-setting mechanisms
April 1, 2026
Policymakers shouldn’t double down on the IRA’s flaws with MFN
March 30, 2026
Hospitals drive nearly 80% of the U.S. health spending gap
March 25, 2026
MFN drug pricing risks reviving a harmful metric the U.S. rejected
March 16, 2026
Leadership in biopharmaceutical R&D provides U.S. patients the greatest access to innovative medicines
March 11, 2026
New report from Minnesota: 340B is generating billions for big hospitals
March 9, 2026
Harmful U.S. policies will help drive China’s global leadership in biopharmaceutical innovation
March 4, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
No hassle, hidden markups or fees: AmericasMedicines.com
February 19, 2026
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
February 17, 2026
Separating fact from fiction in the medicine supply chain
February 11, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
50-state poll says Americans are concerned that hospital markups hurt patients
January 27, 2026
Three things you should know from the insurer CEO congressional hearings
January 26, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
Can’t get your medicine? Don’t count on your insurer.
January 15, 2026
Myth vs. Fact: How government price setting impacts innovation
November 24, 2025
The IRA’s price setting doesn’t guarantee lower costs or better access
November 17, 2025
Stop, collaborate and re-evaluate: ICER’s pricing report
November 14, 2025
California’s landmark PBM crackdown: A wake-up call for reform
November 13, 2025
Middlemen mark up drug prices and keep discounts meant for you
November 10, 2025
PhRMA calls on USTR to ensure foreign nations pay their fair share
November 4, 2025
Putting patients first: Breaking down barriers to care
October 28, 2025
Direct purchase programs can lower costs for patients
October 20, 2025
What seniors can expect this open enrollment
October 14, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
PBMs say they want lower priced medicines, so why don’t they cover them?
October 7, 2025
Historic biopharmaceutical investments: A prescription for America’s future
September 29, 2025
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
September 15, 2025
Medical innovation takes center stage in state legislatures
August 27, 2025
PBMs are hiding hurdles to essential care
August 20, 2025
Celebrating 60 Years of Medicare
July 30, 2025
New study: PBMs and commercial insurers are quietly blocking prescription access
July 30, 2025
North Carolina puts patients first with rebate pass-through law
July 29, 2025
PBMs, not patents, are blocking access to lower-cost medicines
July 23, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
CMS continues to make a bad law worse
June 27, 2025
ICYMI: Forget Foreign Price Controls: There’s a better solution to lowering drug prices
June 26, 2025
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
June 17, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
How the 340B hospital markup program could hurt Michigan patients
June 12, 2025
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
May 21, 2025
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
May 16, 2025
Foreign first pricing schemes don’t address why Americans pay more
May 15, 2025
The AHIP premium dollar corrected (again)
May 8, 2025
PBMs launch new ad campaign to block reforms
May 5, 2025
New analysis: Fewer treatments and cures under the IRA’s pill penalty
May 1, 2025
When middlemen own it all, patients pay the price
April 10, 2025
How the IRA is impacting the generic drug market
April 8, 2025
3 myths critics get wrong about intellectual property
March 28, 2025
New report finds more abuse of 340B program by hospitals and drug middlemen
March 24, 2025
Three reasons Congress should fix the IRA’s pill penalty
March 24, 2025
A closer look at how health care consolidation drives up patient costs, creates barriers to care
March 17, 2025
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
March 13, 2025
Congress Keeps PBMs in the Hot Seat
March 6, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Virginia, Don't Let Politicians Take Away Your Medicine
January 23, 2025
Patients are losing as government price setting continues
January 17, 2025
Wrapping up the J.P. Morgan Healthcare Conference
January 16, 2025
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
January 14, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
New study: Entities that don’t make medicines get half of what is spent on those medicines
January 7, 2025
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
Three things to know about 340B contract pharmacies
November 12, 2024
The PBM industry's desperate attempt to stop reform
November 12, 2024
PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs
November 11, 2024
CMS needs to do better
November 4, 2024
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
October 31, 2024
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
Guest Post: My health care vote
October 29, 2024
Insurers continue shifting more costs on to patients
October 28, 2024
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
October 28, 2024
ICYMI: The powerful companies driving local drugstores out of business
October 25, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
7 reasons why states shouldn’t copy the IRA’s price setting mistake
October 15, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
Hispanic Heritage Month: Fighting for Hispanic patients
October 7, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
September 24, 2024
Three ways state drug price setting boards fail patients
September 18, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
Did the administration consider the importance of autoimmune disease medicines to patients in price setting process?
September 11, 2024
Key voter insights two months from Election Day
September 10, 2024
Patient priorities in the 2024 election
September 10, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
Don’t put the government between patients and their medicines
August 7, 2024
Biosimilars continue to drive market competition and increase savings for seniors
August 6, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
July 30, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
July 19, 2024
PhRMA launches new ad in campaign exposing ways middlemen drive up costs
July 17, 2024
FTC report confirms PBMs profit at the expense of patients
July 10, 2024
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
July 9, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
July 2, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
ICYMI: What patients care about this election year
June 24, 2024
ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs
June 21, 2024
ICYMI: Health care policy should be driven by patients, not politics
June 10, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
June 5, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
How the IRA is more coercive than any European government price setting scheme
May 29, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
How government price setting fails to address systemic health care inequities
May 24, 2024
Ongoing federal probes shed light on PBM and insurer practices
May 20, 2024
Biopharmaceutical industry supports jobs and drives economic growth across the United States
May 16, 2024
Government price-setting boards: Why Minnesota needs to take a better approach
May 9, 2024
WTAS: The consequences of consolidation and vertical integration
May 6, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
Government price setting won’t help patients in Illinois
April 22, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
New analysis: Flawed assessments of a medicine’s value jeopardize patient access
April 11, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
PBMs using 340B program to drive profits at patients’ expense
March 28, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
Colorado is proof: Too many unanswered questions remain about state government price setting's impact on patients and providers
March 14, 2024
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
February 29, 2024
American Heart Month: A nurse’s perspective
February 27, 2024
The truth about Nebraska's price setting push
February 13, 2024
Four years later, Maryland board still hasn’t delivered for patients
February 12, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
Biosimilars drive savings, but the IRA undermines their development
December 14, 2023
How the 340B program became a PBM giveaway
December 11, 2023
ICYMI: When middlemen get in the way, it’s the patients who lose
December 5, 2023
Get the facts on PCMA’s newest attempt to avoid accountability
December 4, 2023
New analysis of patient access restrictions in the United Kingdom
November 21, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
Don't close the door on rare disease research
November 13, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
One year to Election Day: Four voter priorities to watch
November 6, 2023
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
October 25, 2023
New poll shows strong bipartisan support for PBM reform
October 20, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
Three things economists are saying about the Inflation Reduction Act
October 11, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
New analysis shows PBMs use fees as a profit center
September 18, 2023
It’s PBMs, not patents, blocking competition
September 14, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
Three concerns about Colorado's approach to government price setting
August 23, 2023
With the first list of medicines out, let’s not forget why government price setting is bad policy
August 22, 2023
Michigan proposal jeopardizes access to medicines
August 21, 2023
One year later IRAs unintended consequences are becoming reality
August 16, 2023
AARP’s latest misleading report
August 11, 2023
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
July 26, 2023
Three things to know from the latest Patient Experience Survey
July 20, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Four things for CMS to keep in mind as they implement changes to Part D
June 7, 2023
ICYMI: PBM exec admits choosing profits over patients
June 2, 2023